Future perspectives of anticholinergics for the treatment of asthma in adults and children

References

• World Health OrganizationAsthma fact sheet 307 Available from: http://www.who.int/mediacentre/factsheets/fs307/en/Accessed January 24, 2018
   Google Scholar
• Global Burden of Disease 2016 Disease and Injury Incidence and Prevalence CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016Lancet2017390101001211125928919117
   PubMed Web of Science ®Google Scholar
• DemolyPPaggiaroPPlazaVPrevalence of asthma control among adults in France, Germany, Italy, Spain and the UKEur Respir Rev20091811210511220956130
   PubMedGoogle Scholar
• PriceDMathiesonNMulgirigamaAP17 The burden of ICS/LABA-treated asthma patients in the UK adult populationThorax201368Suppl 3A82
   PubMed Web of Science ®Google Scholar
• SchmierJKManjunathRHalpernMTJonesMLThompsonKDietteGBThe impact of inadequately controlled asthma in urban children on quality of life and productivityAnn Allergy Asthma Immunol200798324525117378255
   PubMed Web of Science ®Google Scholar
• PriceDFletcherMvan der MolenTAsthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) surveyNPJ Prim Care Respir Med20142411400924921985
   PubMed Web of Science ®Google Scholar
• CustovicAJohnstonSLPavordIEAACI position statement on asthma exacerbations and severe asthmaAllergy201368121520153124410781
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaGINA report: global strategy for asthma management and prevention Available from: http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed October 22, 2018
   Google Scholar
• JenkinsCTiotropium in adults with asthma: current management strategiesTher Clin Risk Manag2018
   Web of Science ®Google Scholar
• GoldsteinSClinical efficacy and safety of anticholinergic therapies in pediatric patientsTher Clin Risk Manag2018
   Web of Science ®Google Scholar
• Boehringer IngelheimAsthma: Expanded indication for SPIRIVA^® Respimat^® for people 6 years and older Available from: https://www.boehringer-ingelheim.com/press-release/expanded-asthma-indication-spiriva-respimat-euAccessed October 22, 2018
   Google Scholar
• U.S. Food and Drug AdministrationPrescribing information for Spiriva^® Respimat^® (tiotropium bromide) inhalation spray, for oral inhalation Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021936s007lbl.pdfAccessed October 22, 2018
   Google Scholar
• KerstjensHAEngelMDahlRTiotropium in asthma poorly controlled with standard combination therapyN Engl J Med2012367131198120722938706
   PubMed Web of Science ®Google Scholar
• KerstjensHACasaleTBBleeckerERTiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trialsLancet Respir Med20153536737625682232
   PubMed Web of Science ®Google Scholar
• HamelmannEBatemanEDVogelbergCTiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trialJ Allergy Clin Immunol2016138244145026960245
   PubMed Web of Science ®Google Scholar
• HamelmannEBernsteinJAVandewalkerMA randomised controlled trial of tiotropium in adolescents with severe symptomatic asthmaEur Respir J2017491160110027811070
   PubMed Web of Science ®Google Scholar
• VogelbergCEngelMLakiITiotropium add-on therapy improves lung function in children with symptomatic moderate asthmaJ Allergy Clin Immunol Pract2018662160216229751157
   PubMed Web of Science ®Google Scholar
• SzeflerSJMurphyKHarperTA phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthmaJ Allergy Clin Immunol201714051277128728189771
   PubMed Web of Science ®Google Scholar
• VrijlandtEEl AzziGVandewalkerMSafety and efficacy of tiotropium in children aged 1–5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trialLancet Respir Med20186212713729361462
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHEfficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: a systematic reviewPediatr Allergy Immunol201728657357828692145
   PubMed Web of Science ®Google Scholar
• VogelbergCMoroni-ZentgrafPLeonaviciute-KlimantavicieneMA randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroidsRespir Res20151612025851298
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationPrescribing information for XOLAIR^® (omalizumab) Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdfAccessed November 1, 2017
   Google Scholar
• PharmaTCINQAIR – Summary of Product Characteristics Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdfAccessed June 1, 2018
   Google Scholar
• GlaxoSmithKline UKNUCALA summary of product characteristics Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdfAccessed June 1, 2018
   Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med Overseas Ed20143711311981207
   PubMed Web of Science ®Google Scholar
• BjermerLLemiereCMasperoJWeissSZangrilliJGerminaroMReslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized Phase 3 StudyChest2016150478979827056586
   PubMed Web of Science ®Google Scholar
• AstraZeneca plcAstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.htmlAccessed June 1, 2018
   Google Scholar
• CastroMCorrenJPavordIDDupilumab efficacy and safety in moderate-to-severe uncontrolled asthmaN Engl J Med2018378262486249629782217
   PubMed Web of Science ®Google Scholar
• RabeKFNairPBrusselleGEfficacy and safety of dupilumab in glucocorticoid-dependent severe asthmaN Engl J Med2018378262475248529782224
   PubMed Web of Science ®Google Scholar
• WenzelSCastroMCorrenJDupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialLancet201638810039314427130691
   PubMed Web of Science ®Google Scholar
• CarusoMMorjariaJEmmaRAmaradioMDPolosaRBiologic agents for severe asthma patients: clinical perspectives and implicationsIntern Emerg Med201813215517629238905
   PubMed Web of Science ®Google Scholar
• ChangABosséYTargeting single molecules in asthma benefits fewTrends Mol Med2016221193594527692867
   PubMed Web of Science ®Google Scholar
• WalshLJWongCAOborneJAdverse effects of oral corticosteroids in relation to dose in patients with lung diseaseThorax200156427928411254818
   PubMed Web of Science ®Google Scholar
• LefebvrePDuhMSLafeuilleMHAcute and chronic systemic corticosteroid-related complications in patients with severe asthmaJ Allergy Clin Immunol201513661488149526414880
   PubMed Web of Science ®Google Scholar
• GibsonPGYangIAUphamJWEffect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trialLancet20173901009565966828687413
   PubMed Web of Science ®Google Scholar
• WahidiMMKraftMBronchial thermoplasty for severe asthmaAm J Respir Crit Care Med2012185770971422077066
   PubMed Web of Science ®Google Scholar
• DonohueJFWiseRBusseWWEfficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trialBMC Pulm Med20161616527130202
   PubMed Web of Science ®Google Scholar
• CazzolaMOraJRoglianiPMateraMGRole of muscarinic antagonists in asthma therapyExpert Rev Respir Med201711323925328140686
   PubMed Web of Science ®Google Scholar
• MeursHOenemaTAKistemakerLEGosensRA new perspective on muscarinic receptor antagonism in obstructive airways diseasesCurr Opin Pharmacol201313331632323643733
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbHSpiriva Respimat 2.5 microgram, solution for inhalation – Summary of Product Characteristics, Europe Available from: https://www.boehringer-ingelheim.com/products/prescription_medicines/respiratory/asthma/spiriva/public/images/14-3946-Blatter-SPC-Spiriva-ERS.pdfAccessed June 22, 2014
   Google Scholar
• HerediaJLTiotropium bromide: an updateOpen Respir Med J200931435219461900
   PubMedGoogle Scholar
• BarnesPJThe pharmacological properties of tiotropiumChest20001172 Suppl63S66S10673478
   PubMed Web of Science ®Google Scholar
• KoumisTSamuelSTiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary diseaseClin Ther200527437739215922812
   PubMed Web of Science ®Google Scholar
• MoultonBCFryerADMuscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPDBr J Pharmacol20111631445221198547
   PubMed Web of Science ®Google Scholar
• WardMJFentemPHSmithWHDaviesDIpratropium bromide in acute asthmaBr Med J (Clin Res Ed)19812826264598600
   PubMed Web of Science ®Google Scholar
• LougheedMDLemièreCdellSDCanadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for children six years of age and over, and adultsCan Respir J2010171152420186367
   PubMed Web of Science ®Google Scholar
• GriffithsBDucharmeFMCombined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in childrenCochrane Database Syst Rev2013218CD000060
   Google Scholar
• RodrigoGJCastro-RodriguezJAAnticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysisThorax200560974074616055613
   PubMed Web of Science ®Google Scholar
• JolobeOMAsthma vs. non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugsRespiration19844532372426235559
   PubMed Web of Science ®Google Scholar
• McdonaldNJBaraAIAnticholinergic therapy for chronic asthma in children over two years of ageCochrane Database Syst Rev20033CD003535
   Google Scholar
• WestbyMBensonMGibsonPAnticholinergic agents for chronic asthma in adultsCochrane Database Syst Rev20043CD003269
   PubMedGoogle Scholar
• BeehKMMoroni-ZentgrafPAblingerOTiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthmaRespir Res20141516124890738
   PubMed Web of Science ®Google Scholar
• KerstjensHADisseBSchröder-BaboWTiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trialJ Allergy Clin Immunol2011128230831421636120
   PubMed Web of Science ®Google Scholar
• BatemanEDKornmannOSchmidtPPivovarovaAEngelMFabbriLMTiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthmaJ Allergy Clin Immunol2011128231532221807250
   PubMed Web of Science ®Google Scholar
• BeehKMKirstenAMDusserDPharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of Tiotropium Respimat® in asthma using standardized sample- contamination avoidanceJ Aerosol Med Pulm Drug Deliv201629540641526859538
   PubMed Web of Science ®Google Scholar
• TimmerWMoroni-ZentgrafPCornelissenPUnseldAPizzichiniEBuhlROnce-daily tiotropium Respimat® 5 µg is an efficacious 24-h bronchodilator in adults with symptomatic asthmaRespir Med2015109332933825661281
   PubMed Web of Science ®Google Scholar
• PaggiaroPHalpinDMBuhlRThe effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trialJ Allergy Clin Immunol Pract20164110411326563670
   PubMed Web of Science ®Google Scholar
• VogelbergCEngelMMoroni-ZentgrafPTiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging studyRespir Med201410891268127625081651
   PubMed Web of Science ®Google Scholar
• OhtaKIchinoseMTohdaYLong-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled studyPLoS One2015104e012410925894430
   PubMed Web of Science ®Google Scholar
• PetersSPKunselmanSJIcitovicNTiotropium bromide step-up therapy for adults with uncontrolled asthmaN Engl J Med2010363181715172620979471
   PubMed Web of Science ®Google Scholar
• SharmaASchmidMRappBMoroni-ZentgrafPEngelMPharmacokinetics of tiotropium in asthma patients from three paediatric clinical trialsEur Respir J201648PA316
   Web of Science ®Google Scholar
• KerstjensHAMoroni-ZentgrafPTashkinDPTiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic statusRespir Med201611719820627492532
   PubMed Web of Science ®Google Scholar
• CasaleTBBatemanEDAalbersROnce-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristicsEur Respir J201750PA647
   Web of Science ®Google Scholar
• VandewalkerMVogelbergCHamelmannETiotropium Respimat® add-on therapy improves lung function in adolescents and children with moderate symptomatic asthma, irrespective of IgE levels and eosinophil countPoster P521 presented at: The American Thoracic Society International ConferenceMay 19–24, 2016Washington, DC
   Google Scholar
• GoldsteinSVogelbergCHamelmannETiotropium Respimat® add-on therapy is effective in children and adolescents with severe symptomatic asthma, irrespective of immunoglobulin E levels and eosinophil countPoster P520 presented at: The American Thoracic Society International ConferenceMay 19–24, 2016Washington, DC
   Google Scholar
• HamelmannEVogelbergCVoelkerBTiotropium add-on therapy improves lung function in children and adolescents with moderate and severe symptomatic asthma, independent of markers of allergic statusAllergy201772S1030659
   Web of Science ®Google Scholar
• KangJYRheeCKKimJSEffect of tiotropium bromide on airway remodeling in a chronic asthma modelAnn Allergy Asthma Immunol20121091293522727154
   PubMed Web of Science ®Google Scholar
• OhtaSOdaNYokoeTEffect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthmaClin Exp Allergy20104081266127520337647
   PubMed Web of Science ®Google Scholar
• BosnjakBTilpCTomsicCTiotropium bromide inhibits relapsing allergic asthma in BALB/c micePulm Pharmacol Ther2014271445124090641
   PubMed Web of Science ®Google Scholar
• LeeLABriggsAEdwardsLDYangSPascoeSA randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthmaRespir Med20151091637325464907
   PubMed Web of Science ®Google Scholar
• YangSGoyalNBeeraheeMTrivediRLeeLPascoeSDose- response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthmaEur J Clin Pharmacol20157191051105826174114
   PubMed Web of Science ®Google Scholar
• LeeLAYangSKerwinETrivediREdwardsLDPascoeSThe effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging studyRespir Med20151091546225452139
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov (US)A phase III parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination (FDC) of fluticasone furoate+umeclidinium bromide+vilanterol (FF/UMEC/VI) with the FDC of FF/VI in subjects with inadequately controlled asthma (NCT02924688) Available from: https://clinicaltrials.gov/ct2/show/NCT02924688Accessed October 11, 2017
   Google Scholar
• BlaisCMDavisBECockcroftDWDuration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmaticsRespir Med20161189610127578477
   PubMed Web of Science ®Google Scholar
• HanselTTNeighbourHErinEMGlycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthmaChest200512841974197916236844
   PubMed Web of Science ®Google Scholar
• AntoniuSAAclidinium bromide in experimental asthmaExpert Opin Investig Drugs2011206871873
   PubMed Web of Science ®Google Scholar
• DameraGJiangMZhaoHAclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammationEur J Pharmacol20106491–334935320868661
   PubMed Web of Science ®Google Scholar
• BatemanEDBousheyHABousquetJCan guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control studyAm J Respir Crit Care Med2004170883684415256389
   PubMed Web of Science ®Google Scholar
• TanKSGroveAMcleanAGnosspeliusYHallIPLipworthBJSystemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patientsAm J Respir Crit Care Med1997156128359230722
   PubMed Web of Science ®Google Scholar
• YatesDHSussmanHSShawMJBarnesPJChungKFRegular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatmentAm J Respir Crit Care Med19951524117011747551366
   PubMed Web of Science ®Google Scholar
• EvansDJKewKMAndersonDEBoyterACLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaCochrane Database Syst Rev2015217CD011437
   Google Scholar
• KewKMEvansDJAllisonDEBoyterACLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthmaCochrane Database Syst Rev201526CD011438
   Google Scholar
• PetersSPBleeckerERKunselmanSJPredictors of response to tiotropium versus salmeterol in asthmatic adultsJ Allergy Clin Immunol201313251068107424084072
   PubMed Web of Science ®Google Scholar
• BenschGBergerWEBlokhinBMOne-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthmaAnn Allergy Asthma Immunol200289218019012197575
   PubMed Web of Science ®Google Scholar
• NelsonHSWeissSTBleeckerERYanceySWDorinskyPMSMART Study GroupThe Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolChest20061291152616424409
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence2014Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler Available from: https://www.nice.org.uk/advice/esnm34/chapter/Key-points-from-the-evidenceAccessed June 1, 2018
   Google Scholar
• HolgateSTBousquetJChungKFSummary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthmaRespir Med200498647948715191031
   PubMed Web of Science ®Google Scholar
• LemanskeRFMaugerDTSorknessCAStep-up therapy for children with uncontrolled asthma receiving inhaled corticosteroidsN Engl J Med Overseas Ed201036211975985
   PubMed Web of Science ®Google Scholar
• Castro-RodriguezJARodrigoGJThe role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysisArch Dis Child201095536537019946008
   PubMed Web of Science ®Google Scholar
• ChauhanBFBen SalahRDucharmeFMAddition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthmaCochrane Database Syst Rev2013210CD009585
   Google Scholar
• ZhangLPrietschSODucharmeFMInhaled corticosteroids in children with persistent asthma: effects on growthEvid Based Child Health20149482993025504972
   PubMedGoogle Scholar
• PruteanuAIChauhanBFZhangLPrietschSODucharmeFMInhaled corticosteroids in children with persistent asthma: dose-response effects on growthCochrane Database Syst Rev2014177CD009878
   Google Scholar
• RabeKFAdachiMLaiCKWorldwide severity and control of asthma in children and adults: the global asthma insights and reality surveysJ Allergy Clin Immunol20041141404715241342
   PubMed Web of Science ®Google Scholar
• FitzgeraldJMBouletLPMcivorRAZimmermanSChapmanKRAsthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) studyCan Respir J200613525325916896426
   PubMedGoogle Scholar
• SpectorSNoncompliance with asthma therapy – are there solutions?J Asthma200037538138810983615
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPBenayounSBaltzanMCaiBLow-dose inhaled corticosteroids and the prevention of death from asthmaN Engl J Med Overseas Ed20003435332336
   PubMed Web of Science ®Google Scholar
• Inhaler Error Steering CommitteePriceDBosnic-AnticevichSInhaler competence in asthma: common errors, barriers to use and recommended solutionsRespir Med20131071374623098685
   PubMed Web of Science ®Google Scholar
• HaughneyJPriceDKaplanAAchieving asthma control in practice: understanding the reasons for poor controlRespir Med2008102121681169318815019
   PubMed Web of Science ®Google Scholar
• GiraudVRocheNMisuse of corticosteroid metered-dose inhaler is associated with decreased asthma stabilityEur Respir J200219224625111866004
   PubMed Web of Science ®Google Scholar
• HodderRReesePRSlatonTAsthma patients prefer Respimat Soft Mist Inhaler to TurbuhalerInt J Chron Obstruct Pulmon Dis2009422523219554196
   PubMedGoogle Scholar
• GadkariASMchorneyCAUnintentional non-adherence to chronic prescription medications: how unintentional is it really?BMC Health Serv Res20121219822510235
   PubMed Web of Science ®Google Scholar
• WilsonSRStrubPBuistASShared treatment decision making improves adherence and outcomes in poorly controlled asthmaAm J Respir Crit Care Med2010181656657720019345
   PubMed Web of Science ®Google Scholar
• FinkJBRubinBKProblems with inhaler use: a call for improved clinician and patient educationRespir Care2005501013741375
   Google Scholar
• McfaddenERImproper patient techniques with metered dose inhalers: clinical consequences and solutions to misuseJ Allergy Clin Immunol19959622782837636071
   PubMed Web of Science ®Google Scholar
• AndersonPUse of Respimat Soft Mist inhaler in COPD patientsInt J Chron Obstruct Pulmon Dis20061325125918046862
   PubMedGoogle Scholar
• Moroni-ZentgrafPImpact of patient needs on design and usage of an inhalation device in respiratory medicineRespir Drug Delivery Euro20131141152
   Google Scholar
• WatchelHKattenbeckKDunneSThe Respimat® development story: patient-centered innovationPulm Ther201731930
   Google Scholar
• de SimoniAHorneRFlemingLBushAGriffithsCWhat do adolescents with asthma really think about adherence to inhalers? Insights from a qualitative analysis of a UK online forumBMJ Open201776e015245
   PubMed Web of Science ®Google Scholar
• SchürmannWSchmidtmannSMoroniPMasseyDQidanMRespimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfactionTreat Respir Med200541536115725050
   PubMedGoogle Scholar
• KaminWFrankMKattenbeckSMoroni-ZentgrafPWachtelHZielenSA Handling study to assess use of the Respimat(®) Soft Mist™ inhaler in children under 5 years oldJ Aerosol Med Pulm Drug Deliv201528537238125844687
   PubMed Web of Science ®Google Scholar
• MarksonLEVollmerWMFittermanLInsight into patient dissatisfaction with asthma treatmentArch Intern Med2001161337938411176763
   PubMedGoogle Scholar
• SmallMAndersonPVickersAKaySFermerSImportance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomesAdv Ther201128320221221331556
   PubMed Web of Science ®Google Scholar
• AccordiniSCorsicoAGBraggionMThe cost of persistent asthma in Europe: an international population-based study in adultsInt Arch Allergy Immunol201316019310122948386
   PubMed Web of Science ®Google Scholar
• ChippsBEZeigerRSBorishLKey findings and clinical implications from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) studyJ Allergy Clin Immunol20121302e10:332342
   Web of Science ®Google Scholar
• WillsonJBatemanEDPavordILloydAKrivasiTEsserDCost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonistsAppl Health Econ Health Policy201412444745924974107
   PubMedGoogle Scholar
• WillsonJBatemanEDPavordILloydAKrivasiTEsserDErratum to: cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonistsAppl Health Econ Health Policy201614111912526816028
   PubMed Web of Science ®Google Scholar
• PawlikMWalczakJPieniazekIEconomic evaluation of tiotropium administrated through the Respimat inhaler as add-on therapy in patients with uncontrolled severe asthma in PolandValue Health2015187A502
   Web of Science ®Google Scholar
• Silva MiguelLManaçasMPinheiroBEconomic evaluation of tiotropium for severe persistent asthma in PortugalValue Health2015187A502
   Web of Science ®Google Scholar
• ZafariZSadatsafaviMMarkFitzGerald JCanadian Respiratory Research NetworkCost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in USCost Eff Resour Alloc2018161329422778
   PubMed Web of Science ®Google Scholar